STOCK TITAN

Constellium Se Financials

CSTM
Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Constellium Se (CSTM) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Profitability Growth Leverage Liquidity Cash Flow Returns 49 / 100
Financial Profile 49/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Growth
59

Constellium Se's revenue surged 15.2% year-over-year to $8.4B, reflecting rapid business expansion. This strong growth earns a score of 59/100.

Leverage
61

Constellium Se has a moderate D/E ratio of 2.00. This balance of debt and equity financing earns a leverage score of 61/100.

Liquidity
21

Constellium Se's current ratio of 1.29 means current assets barely cover short-term liabilities. This tight liquidity results in a low score of 21/100, which could limit financial flexibility.

Cash Flow
30

Constellium Se has a free cash flow margin of 1.9%, earning a moderate score of 30/100. The company generates positive cash flow after capital investments, but with room for improvement.

Returns
75

Constellium Se earns a strong 28.7% return on equity (ROE), meaning it generates $29 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 75/100. This is up from 7.9% the prior year.

Piotroski F-Score Strong
9/9

Constellium Se passes 9 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), all 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Cash-Backed
1.79x

For every $1 of reported earnings, Constellium Se generates $1.79 in operating cash flow ($489.0M OCF vs $273.0M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$8.4B
YoY+15.2%

Constellium Se generated $8.4B in revenue in fiscal year 2025. This represents an increase of 15.2% from the prior year.

EBITDA
N/A
Net Income
$273.0M
YoY+387.5%

Constellium Se reported $273.0M in net income in fiscal year 2025. This represents an increase of 387.5% from the prior year.

EPS (Diluted)
$1.92
YoY+405.3%

Constellium Se earned $1.92 per diluted share (EPS) in fiscal year 2025. This represents an increase of 405.3% from the prior year.

Cash & Balance Sheet

Free Cash Flow
$159.0M
YoY+242.0%

Constellium Se generated $159.0M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 242.0% from the prior year.

Cash & Debt
$120.0M
YoY-14.9%

Constellium Se held $120.0M in cash against $1.9B in long-term debt as of fiscal year 2025.

Dividends Per Share
N/A
Shares Outstanding
135M
YoY-5.9%

Constellium Se had 135M shares outstanding in fiscal year 2025. This represents a decrease of 5.9% from the prior year.

Margins & Returns

Gross Margin
14.1%
YoY+1.3pp

Constellium Se's gross margin was 14.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 1.3 percentage points from the prior year.

Operating Margin
N/A
Net Margin
3.2%
YoY+2.5pp

Constellium Se's net profit margin was 3.2% in fiscal year 2025, showing the share of revenue converted to profit. This is up 2.5 percentage points from the prior year.

Return on Equity
28.7%
YoY+20.8pp

Constellium Se's ROE was 28.7% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 20.8 percentage points from the prior year.

Capital Allocation

R&D Spending
$51.0M
YoY+4.1%

Constellium Se invested $51.0M in research and development in fiscal year 2025. This represents an increase of 4.1% from the prior year.

Share Buybacks
$115.0M
YoY+45.6%

Constellium Se spent $115.0M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents an increase of 45.6% from the prior year.

Capital Expenditures
$330.0M
YoY-20.1%

Constellium Se invested $330.0M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 20.1% from the prior year.

CSTM Income Statement

Metric Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24 Q2'24 Q1'24
Revenue $2.2B+1.6% $2.2B+3.0% $2.1B+6.3% $2.0B+15.0% $1.7B-4.5% $1.8B-6.7% $1.9B+2.8% $1.9B
Cost of Revenue $1.9B+0.1% $1.9B+0.7% $1.8B+7.2% $1.7B+13.4% $1.5B-5.3% $1.6B-3.3% $1.7B+1.0% $1.6B
Gross Profit $347.0M+10.5% $314.0M+19.4% $263.0M0.0% $263.0M+26.4% $208.0M+1.5% $205.0M-26.8% $280.0M+14.3% $245.0M
R&D Expenses $14.0M+16.7% $12.0M0.0% $12.0M-7.7% $13.0M+30.0% $10.0M-9.1% $11.0M-15.4% $13.0M-13.3% $15.0M
SG&A Expenses $81.0M-4.7% $85.0M-3.4% $88.0M+12.8% $78.0M-15.2% $92.0M+39.4% $66.0M-12.0% $75.0M-6.3% $80.0M
Operating Income N/A N/A N/A N/A N/A N/A N/A N/A
Interest Expense $25.0M-7.4% $27.0M+8.0% $25.0M0.0% $25.0M-7.4% $27.0M+8.0% $25.0M+13.6% $22.0M-12.0% $25.0M
Income Tax $51.0M+34.2% $38.0M+90.0% $20.0M-16.7% $24.0M-17.2% $29.0M+163.6% $11.0M-59.3% $27.0M+237.5% $8.0M
Net Income $112.0M+27.3% $88.0M+144.4% $36.0M-2.7% $37.0M+177.1% -$48.0M-785.7% $7.0M-90.8% $76.0M+261.9% $21.0M
EPS (Diluted) N/A $0.62+148.0% $0.25-3.8% $0.26 N/A $0.05-90.2% $0.51+264.3% $0.14

CSTM Balance Sheet

Metric Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24 Q2'24 Q1'24
Total Assets $5.4B-0.4% $5.4B+0.1% $5.4B+3.9% $5.2B+9.2% $4.7B N/A N/A N/A
Current Assets $2.3B-1.3% $2.4B+1.8% $2.3B+3.4% $2.2B+21.9% $1.8B N/A N/A N/A
Cash & Equivalents $120.0M-1.6% $122.0M-8.3% $133.0M+12.7% $118.0M-16.3% $141.0M-17.1% $170.0M-25.4% $228.0M+17.5% $194.0M
Inventory $1.4B+3.0% $1.4B+2.9% $1.3B+3.9% $1.3B+8.2% $1.2B N/A N/A N/A
Accounts Receivable $611.0M-11.8% $693.0M+2.1% $679.0M+2.1% $665.0M+74.5% $381.0M N/A N/A N/A
Goodwill $47.0M0.0% $47.0M0.0% $47.0M+2.2% $46.0M0.0% $46.0M N/A N/A N/A
Total Liabilities $4.4B-2.9% $4.5B-1.2% $4.6B+3.8% $4.4B+9.9% $4.0B N/A N/A N/A
Current Liabilities $1.8B-2.4% $1.8B-1.7% $1.9B+3.6% $1.8B+25.0% $1.4B N/A N/A N/A
Long-Term Debt $1.9B-3.5% $2.0B+0.1% $2.0B+3.4% $1.9B+1.5% $1.9B N/A N/A N/A
Total Equity $952.0M+12.7% $845.0M+8.3% $780.0M+4.7% $745.0M+5.5% $706.0M-12.2% $804.0M+1.0% $796.0M+6.0% $751.0M
Retained Earnings $354.0M N/A N/A N/A $93.0M N/A N/A N/A

CSTM Cash Flow Statement

Metric Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24 Q2'24 Q1'24
Operating Cash Flow $218.0M+120.2% $99.0M-13.2% $114.0M+96.6% $58.0M-4.9% $61.0M-6.2% $65.0M-52.9% $138.0M+273.0% $37.0M
Capital Expenditures $109.0M+45.3% $75.0M-2.6% $77.0M+11.6% $69.0M-54.3% $151.0M+45.2% $104.0M+23.8% $84.0M+13.5% $74.0M
Free Cash Flow $109.0M+354.2% $24.0M-35.1% $37.0M+436.4% -$11.0M+87.8% -$90.0M-130.8% -$39.0M-172.2% $54.0M+245.9% -$37.0M
Investing Cash Flow -$109.0M-58.0% -$69.0M+4.2% -$72.0M-22.0% -$59.0M+52.8% -$125.0M-62.3% -$77.0M-26.2% -$61.0M-22.0% -$50.0M
Financing Cash Flow -$112.0M-173.2% -$41.0M-13.9% -$36.0M-38.5% -$26.0M-157.8% $45.0M+181.8% -$55.0M-34.1% -$41.0M-310.0% -$10.0M
Dividends Paid N/A N/A N/A N/A N/A N/A N/A N/A
Share Buybacks $40.0M+60.0% $25.0M-28.6% $35.0M+133.3% $15.0M-21.1% $19.0M-9.5% $21.0M-34.4% $32.0M+357.1% $7.0M

CSTM Financial Ratios

Metric Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24 Q2'24 Q1'24
Gross Margin 15.8%+1.3pp 14.5%+2.0pp 12.5%-0.8pp 13.3%+1.2pp 12.1%+0.7pp 11.4%-3.1pp 14.5%+1.5pp 13.0%
Operating Margin N/A N/A N/A N/A N/A N/A N/A N/A
Net Margin 5.1%+1.0pp 4.1%+2.3pp 1.7%-0.2pp 1.9%+4.7pp -2.8%-3.2pp 0.4%-3.5pp 3.9%+2.8pp 1.1%
Return on Equity 11.8%+1.3pp 10.4%+5.8pp 4.6%-0.4pp 5.0%+11.8pp -6.8%-7.7pp 0.9%-8.7pp 9.6%+6.8pp 2.8%
Return on Assets 2.1%+0.4pp 1.6%+1.0pp 0.7%-0.0pp 0.7%+1.7pp -1.0% N/A N/A N/A
Current Ratio 1.29+0.0 1.28+0.0 1.230.0 1.24-0.0 1.27 N/A N/A N/A
Debt-to-Equity 2.00-0.3 2.34-0.2 2.53-0.0 2.56-0.1 2.66 N/A N/A N/A
FCF Margin 5.0%+3.8pp 1.1%-0.7pp 1.8%+2.3pp -0.6%+4.7pp -5.2%-3.1pp -2.2%-5.0pp 2.8%+4.8pp -2.0%

Similar Companies

Frequently Asked Questions

Constellium Se (CSTM) reported $8.4B in total revenue for fiscal year 2025. This represents a 15.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Constellium Se (CSTM) revenue grew by 15.2% year-over-year, from $7.3B to $8.4B in fiscal year 2025.

Yes, Constellium Se (CSTM) reported a net income of $273.0M in fiscal year 2025, with a net profit margin of 3.2%.

Constellium Se (CSTM) reported diluted earnings per share of $1.92 for fiscal year 2025. This represents a 405.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

As of fiscal year 2025, Constellium Se (CSTM) had $120.0M in cash and equivalents against $1.9B in long-term debt.

Constellium Se (CSTM) had a gross margin of 14.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

Constellium Se (CSTM) had a net profit margin of 3.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Constellium Se (CSTM) has a return on equity of 28.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Constellium Se (CSTM) generated $159.0M in free cash flow during fiscal year 2025. This represents a 242.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Constellium Se (CSTM) generated $489.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

Constellium Se (CSTM) had $5.4B in total assets as of fiscal year 2025, including both current and long-term assets.

Constellium Se (CSTM) invested $330.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Constellium Se (CSTM) invested $51.0M in research and development during fiscal year 2025.

Yes, Constellium Se (CSTM) spent $115.0M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

Constellium Se (CSTM) had 135M shares outstanding as of fiscal year 2025.

Constellium Se (CSTM) had a current ratio of 1.29 as of fiscal year 2025, which is considered adequate.

Constellium Se (CSTM) had a debt-to-equity ratio of 2.00 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

Constellium Se (CSTM) had a return on assets of 5.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Constellium Se (CSTM) has a Piotroski F-Score of 9 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Constellium Se (CSTM) has an earnings quality ratio of 1.79x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Constellium Se (CSTM) scores 49 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.

Back to top